Market Cap (In USD)
1.27 Billion
Revenue (In USD)
78.5 Million
Net Income (In USD)
-367.3 Million
Avg. Volume
715.4 Thousand
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 18.17-53.08
- PE
- -
- EPS
- -
- Beta Value
- 1.967
- ISIN
- US04335A1051
- CUSIP
- 04335A105
- CIK
- 1655759
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. John G. Houston Ph.D.
- Employee Count
- -
- Website
- https://www.arvinas.com
- Ipo Date
- 2018-09-27
- Details
- Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.
More Stocks
-
CPCAF
-
002792Tongyu Communication Inc.
002792
-
300109
-
AVIFY
-
HSD
-
WCCP
-
002286Baolingbao Biology Co.,Ltd.
002286
-
BHARATGEARBharat Gears Limited
BHARATGEAR